Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
122932514 | 12293251 | 4 | F | 20160302 | 20160803 | 20160421 | 20160815 | EXP | US-TEVA-653566USA | TEVA | 67.61 | YR | F | Y | 0.00000 | 20160815 | OT | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
122932514 | 12293251 | 1 | PS | CLOZAPINE. | CLOZAPINE | 1 | Oral | Y | 74949 | TABLET | |||||||||
122932514 | 12293251 | 2 | C | SEROQUEL | QUETIAPINE FUMARATE | 1 | 300MG AM, 100MG 5PM, 350 MG HS | Y | 0 | ||||||||||
122932514 | 12293251 | 3 | C | LEXAPRO | ESCITALOPRAM OXALATE | 1 | 0 | QD | |||||||||||
122932514 | 12293251 | 4 | C | CLONAZEPAM. | CLONAZEPAM | 1 | AT HS | 0 | |||||||||||
122932514 | 12293251 | 5 | C | COLACE | DOCUSATE SODIUM | 1 | 0 | ||||||||||||
122932514 | 12293251 | 6 | C | MIRALAX | POLYETHYLENE GLYCOL 3350 | 1 | 0 | ||||||||||||
122932514 | 12293251 | 7 | C | CALCIUM | CALCIUM | 1 | 0 |
Indications of drugs used
no results found |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
122932514 | 12293251 | OT |
122932514 | 12293251 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
122932514 | 12293251 | Agranulocytosis | |
122932514 | 12293251 | Leukopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |